Biomarker Seeking Series A Funds for Blood Test Studies

Biomarker Technologies, a worldwide technology provider of the BT Test -- a blood diagnostic for the detection of breast cancer -- announced it is seeking to raise Series A Funding to conduct clinical studies of the in-vitro diagnostic test for subsequent FDA approval. The company received initial funding in 2004 from angel investors and is in due diligence with numerous potential licensees. "This funding is critical to help us expedite the FDA approval process," said William Gartner, CEO and president of Biomarker Technologies.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050419005017&newsLang=en)